key: cord-0802327-59n2ijmk authors: Fanaroff, Alexander C.; Califf, Robert M.; Harrington, Robert A.; Granger, Christopher B.; McMurray, John J.V.; Patel, Manesh R.; Bhatt, Deepak L.; Windecker, Stephan; Hernandez, Adrian F.; Gibson, C. Michael; Alexander, John H.; Lopes, Renato D. title: Randomized Trials Versus Common Sense and Clinical Observation: JACC Review Topic of the Week date: 2020-08-04 journal: J Am Coll Cardiol DOI: 10.1016/j.jacc.2020.05.069 sha: f395e755237b2ab4decc7aff674dc3d8f2b57967 doc_id: 802327 cord_uid: 59n2ijmk Concerns about the external validity of traditional randomized clinical trials (RCTs), together with the widespread availability of real-world data and advanced data analytic tools, have led to claims that common sense and clinical observation, rather than RCTs, should be the preferred method to generate evidence to support clinical decision-making. However, over the past 4 decades, results from well-done RCTs have repeatedly contradicted practices supported by common sense and clinical observation. Common sense and clinical observation fail for several reasons: incomplete understanding of pathophysiology, biases and unmeasured confounding in observational research, and failure to understand risks and benefits of treatments within complex systems. Concerns about traditional RCT models are legitimate, but randomization remains a critical tool to understand the causal relationship between treatments and outcomes. Instead, development and promulgation of tools to apply randomization to real-world data are needed to build the best evidence base in cardiovascular medicine. T he digitization of health care has led to the proliferation of "real-world data"-data collected for nonresearch purposes, like patient care or billing-and observational studies based on these data (1) . Expansion of statistical techniques for the analysis of observational data, including the application of machine learning to health care, has accelerated the growth of observational real-world data analyses (2) . At the same time, the growing complexity and cost of traditional randomized clinical trials (RCTs) and a focus by many academic and community health care systems on maximizing clinical volume at the expense of research participation has led to RCTs that enroll selected patients at selected centers (3, 4) . These trends have converged in concerns that RCTs have become too complex and selective to be the preferred method to generate evidence to support clinical decisionmaking (5) (6) (7) . Despite these arguments, RCTs remain the best current method to understand the causal relationship between an intervention and subsequent population-level outcomes for most common chronic illnesses (8) . In the absence of data from RCTs, patients, their families, clinicians, payers, and health systems are forced to rely on "common sense" Common sense may fail because of an incomplete understanding of pathophysiology. One subcategory of this type of failure occurs when a clinical observation merely represents a marker of risk, and not a modifiable target. In the 1970s, investigators identified an association between premature ventricular contractions and mortality following myocardial infarction (MI) (14) , and cardiologists routinely used antiarrhythmic drugs to treat patients with nonsustained ventricular tachycardia (15). When the hypothesis that treating ventricular ectopy with Class I antiarrhythmic drugs would improve outcomes was tested in the randomized controlled CAST (Cardiac Arrhythmia Suppression Trial), patients assigned to antiarrhythmic drugs had higher mortality than those assigned to placebo (16) . The CAST experience was a dramatic example of this type of failure of common sense, but it is far from the only one. In the 1990s, observational studies suggested that patients with a patent infarct-related artery after MI had better survival than those who did not (17) , but the OAT (Occluded Artery Trial) RCT showed that percutaneous revascularization of an occluded infarct-related artery 3 to 28 days after MI did not reduce cardiovascular events over long-term followup (18) . Similarly, epidemiological studies demonstrated an association between low levels of high-density lipoprotein cholesterol (HDL-C) and cardiovascular mortality (19) , but in RCTs, multiple HDL-C-raising drugs did not reduce cardiovascular events (20-24). Another example is myocardial ischemia, which has been associated with increased HIGHLIGHTS Well-conducted RCTs have repeatedly contradicted practices supported by common sense and clinical observation. Common sense and clinical observation fail because of the inability to fully understand complex biopsychosocial systems. RCTs must be integrated into clinical practice to improve the evidence base in cardiology. Fanaroff et al. The Case for RCTs A U G U S T 4 , 2 0 2 0 : 5 8 0 -9 risk of mortality and MI in observational studies (25), but multiple RCTs have shown that relieving ischemia by revascularization does not reduce the risk of mortality or MI (26) (27) (28) . Similarly, anemia has been associated with poor outcomes in patients with heart failure and type 2 diabetes with chronic kidney disease (29, 30) , but randomized controlled trials of erythropoietin analogues in these populations have failed to improve clinical outcomes (31, 32) . Higher heart rates in patients with atrial fibrillation are associated with worse outcomes (33), but tighter heart rate control did not translate into improved outcomes in an RCT (34) . In cardiothoracic surgery, high-quality RCTs have challenged common-sense therapies that relied on modifying disease markers ultimately shown not to be modifiable targets, including ventricular reconstruction to reduce ventricular size in ischemic cardiomyopathy (35) , mitral valve surgery to reduce ischemic mitral regurgitation (36) , and avoidance of coronary artery bypass grafting in ischemic cardiomyopathy patients without myocardial viability (37) . In patients with diabetes mellitus, observational studies, consistent with common sense, showed associations between higher blood pressure and worse glycemic control and worse cardiovascular outcomes (70, 71) . However, when patients with diabetes mellitus were randomized to intensive (<120 mm Hg systolic) or standard (<140 mm Hg systolic) blood pressure control and to intensive (hemoglobin A1c <6%) or standard (hemoglobin A1c 7% to 7.9%) glycemic control, intensive blood pressure control did not reduce the risk of cardiovascular events, and intensive glycemic control lowered the risk of MI but increased the risk of mortality (72, 73) . Both intensive treatment strategies caused a higher likelihood of adverse events compared with standard therapies. Sodium-glucose cotransporter 2 (SGLT2) inhibitors were initially approved for use based on RCTs showing that they were modestly effective glucoselowering agents in patients with type 2 diabetes mellitus. However, the manufacturers of these agents were required by regulatory agencies to perform large RCTs assessing the effect of these agents on cardiovascular outcomes. In the course of these RCTs, there was evidence that SGLT2 inhibitors reduced heart failure hospitalizations (77) , and an RCT in patients with heart failure, with or without diabetes mellitus, The Case for RCTs showed that these agents reduced all-cause death and worsening heart failure (78) . There was no compelling common-sense reason to anticipate this benefit, and without pivotal RCTs, the therapeutic potential of SGLT2 inhibitors in heart failure may never have been realized. Common sense and clinical observation may fail to accurately describe the effect of a treatment on outcomes for multiple reasons. Randomization bypasses these failure mechanisms, creating a controlled experiment to understand the true effect of a treatment on outcomes. When common sense and clinical observation are the basis for treatment decisions, there is great uncertainty about benefit and risk, such that treatments may be ineffective and/or put the patient at risk. In contrast, treatment decisions based on high-quality randomized controlled trials have well-defined benefit and risk profiles allowing for effective decision-making. RCTs to support clinical decision-making (94) . Fewer than 15% of European and American cardiology guideline recommendations are supported by evidence from RCTs, a proportion that has not changed over the past decade (95) . The development of realworld data sources into research-ready platforms, supported by governmental agencies in multiple countries, has highlighted the value of real-world data in identifying rare adverse events related to drugs and devices (96) , but has further underscored the limitations of observational study designs for understanding treatment effects. The critical next step is to apply randomization to real-world data on a broad scale, harnessing the power of randomization to understand treatment effects, and the power of real-world data to generate large, representative, infinitely reusable study populations (97). To do so will require health systems to reinvest in electronic health records to build systems with increased interoperability, and the ability to identify, randomize, and enroll patients in RCTs and then capture research-quality baseline and follow-up data. Such systems would be strengthened by international collaboration to define data standards to enable multinational trials. Health systems may also need to realign priorities to reduce the emphasis on clinical volume in favor of greater emphasis on research and patient care. Regulatory authorities will need to work with researchers to modify regulations that create red tape and stifle creative RCT design, moving toward centralized institutional review boards and uniform language for contracts in multisite RCTs. Last, regulatory authorities should provide clear guidance to the pharmaceutical and device industries on when realworld data is acceptable for regulatory purposes. The Case for RCTs Stroke prevention in atrial fibrillation: re-defining "real-world data" within the broader data universe Real-world evidence, causal inference, and machine learning Hospital participation in clinical trials for patients with acute myocardial infarction: results from the National Cardiovascular Data Registry Trial watch: trends in clinical trial design complexity Real world evidence (RWE)-a disruptive innovation or the quiet evolution of medical evidence generation? Hierarchies of evidence applied to lifestyle Medicine (HEALM): introduction of a strength-of-evidence approach based on a methodological systematic review When and how can real world data analyses substitute for randomized controlled trials? The Magic of randomization versus the myth of realworld evidence Association is not causation: treatment effects cannot be estimated from observational data in heart failure Realworld studies no substitute for RCTs in establishing efficacy Randomization-there is no substitute Navigating the future of cardiovascular drug development-leveraging novel approaches to drive innovation and drug discovery: summary of findings from the novel cardiovascular therapeutics conference Trends in risks associated with new drug development: success rates for investigational drugs Ventricular premature beats and mortality after myocardial infarction Arrhythmia Suppression Trial results were available Mortality and morbidity in patients receiving encainide, flecainide, or placebo Prognosis after acute myocardial infarction in patients with and without residual anterograde coronary blood flow Coronary intervention for persistent occlusion after myocardial infarction HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events Evacetrapib and cardiovascular outcomes in highrisk vascular disease Effects of combination lipid therapy in type 2 diabetes mellitus Effects of extended-release niacin with laropiprant in highrisk patients Effects of dalcetrapib in patients with a recent acute coronary syndrome Effects of torcetrapib in patients at high risk for coronary events Medical therapy with versus without revascularization in stable patients with moderate and severe ischemia: the case for community equipoise Optimal medical therapy with or without PCI for stable coronary disease A randomized trial of therapies for type 2 diabetes and coronary artery disease Initial invasive or conservative strategy for stable coronary disease Anemia and heart failure Hematocrit, independent of chronic kidney disease, predicts adverse cardiovascular outcomes in Chinese patients with type 2 diabetes Treatment of anemia with darbepoetin alfa in systolic heart failure A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease A comparison of low versus high heart rate in patients with atrial fibrillation and advanced chronic heart failure: effects on clinical profile, neurohormones and survival Lenient versus strict rate control in patients with atrial fibrillation Coronary bypass surgery with or without surgical ventricular reconstruction Twoyear outcomes of surgical treatment of moderate ischemic mitral regurgitation Myocardial viability and long-term outcomes in ischemic cardiomyopathy Intraaortic balloon counterpulsation in cardiogenic shock Intraaortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock (IABP-SHOCK II): final 12 month results of a randomised, open-label trial Safety and feasibility of elective high-risk percutaneous coronary intervention procedures with left ventricular support of the Impella Recover LP 2.5 A prospective, randomized clinical trial of hemodynamic support with Impella 2.5 versus intraaortic balloon pump in patients undergoing high-risk percutaneous coronary intervention for the PROMISE Study Research Group. Effect of oral milrinone on mortality in severe chronic heart failure Quality of life in atrial fibrillation: the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study for the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation Rhythm control versus rate control for atrial fibrillation and heart failure Reduced leaflet motion after transcatheter aorticvalve replacement A controlled trial of rivaroxaban after transcatheter aortic-valve replacement Thrombus aspiration during primary percutaneous coronary intervention Thrombus aspiration during ST-segment elevation myocardial infarction Randomized trial of primary PCI with or without routine manual thrombectomy Surrogate end points in clinical trials: are we being misled? Vitamin E consumption and the risk of coronary heart disease in men Vitamin E consumption and the risk of coronary disease in women Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis Serum 25-hydroxyvitamin D and the risk of cardiovascular disease: dose-response meta-analysis of prospective studies Antioxidant vitamins and coronary heart disease risk: a pooled analysis of 9 cohorts Vitamin supplement use in a low-risk population of US male physicians and subsequent cardiovascular mortality Sleight P, for the Heart Outcomes Prevention Evaluation Study Investigators. Vitamin E supplementation and cardiovascular events in high-risk patients Homocysteine lowering with folic acid and B vitamins in vascular disease Homocysteine lowering and cardiovascular events after acute myocardial infarction Vitamin D supplements and prevention of cancer and cardiovascular disease Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial Multivitamins in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial Hormone therapy to prevent disease and prolong life in postmenopausal women for the Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative Randomized Controlled Trial Statin adherence and risk of accidents: a cautionary tale Initial experience with multivessel percutaneous coronary intervention during mechanical reperfusion for acute myocardial infarction Complete revascularization with multivessel PCI for myocardial infarction Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study Glycemic control and coronary heart disease risk in persons with and without diabetes: the atherosclerosis risk in communities study Effects of intensive blood-pressure control in type 2 diabetes mellitus Long-term effects of intensive glucose lowering on cardiovascular outcomes Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study Stroke Prevention in Atrial Fibrillation Study. Final results Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials Dapagliflozin and cardiovascular outcomes in type 2 diabetes Dapagliflozin in patients with heart failure and reduced ejection fraction American industry and the U.S. Cardiovascular Clinical Research Enterprise Real-world evidence -what is it and what can it tell us? Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes Accelerating development of scientific evidence for medical products within the existing US regulatory framework The imperative of overcoming barriers to the conduct of large, simple trials Balanced crystalloids versus saline in noncritically ill adults Creating a learning health system through rapid-cycle, randomized testing Pragmatic clinical trials embedded in healthcare systems: generalizable lessons from the NIH Collaboratory Ticagrelor or prasugrel in patients with acute coronary syndromes Prasugrel versus ticagrelor in patients with acute myocardial infarction treated with primary percutaneous coronary intervention: multicenter randomized PRAGUE-18 Study Risk of death following application of paclitaxel-coated balloons and stents in the femoropopliteal artery of the leg: a systematic review and meta-analysis of randomized controlled trials Paclitaxelrelated balloons and stents for the treatment of peripheral artery disease: insights from the Food and Drug Administration 2019 Circulatory System Devices Panel Meeting on late mortality Rivaroxaban in patients with a recent acute coronary syndrome The ATLAS ACS 2-TIMI 51 trial and the burden of missing data High-quality evidence to inform clinical practice Levels of evidence supporting American College of Cardiology/American Heart Association and European Society of Cardiology Guidelines The FDA Sentinel initiative-an evolving national resource